Volition highlights Nu.Q H3.1 sepsis data, sees $3.8 billion market opportunity

The company said it is in discussions with several large diagnostic companies as clinicians cited consistent international findings for Nu.Q NETs in sepsis and systemic inflammation.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.